Literature DB >> 12226812

Lipopolysaccharide administration increases acid and alkaline phosphatase reactivity in the cardiac muscle.

Teruhiko Okada1, Vadim S Zinchuk, Harumichi Seguchi.   

Abstract

The effect of lipopolysaccharide (LPS) administration on the in situ distribution of the reaction product of acid phosphatase (AcPase) and alkaline phosphatase (AlPase) activity was examined in the rat cardiac muscle using catalytical cytochemistry. Tissues of the heart were fixed and then incubated in reaction media for detection of AcPase and AlPase reactivity. In normal hearts, reaction product of AcPase activity was observed in lysosomes. AlPase reactivity was detected at the extracellular surface of the capillary endothelilal cells and in their caveolae. Following LPS administration, the number and the size of lysosomes possessing AcPase reactivity as well as their electron density significantly increased. Furthermore, they tended to form groups consisting of three to five lysosomes. Cytochemical reaction 2 and 24 hours after injection was similar. One week later, the reaction returned to its normal pattern. As in the case with AcPase, the first changes of the distribution of the reaction product of AlPase activity were detected 2 hours after injection. The changes included a remarkable increase of the number of enzymatically positive capillaries, intensified cytochemical reaction in endothelial cells, and an increased number of caveolae. Again, no noticeable differences in reactivity were observed 2 and 24 hours after injection and the reaction returned to normal one week later. Collectively, our data indicate that both cardiac AcPase and AlPase are affected early after injection of LPS. Although the pattern of cytochemical reaction of both phosphatases was restored one week later, it is believed that the altered distribution of their reactivity in early periods after LPS administration may be a factor contributing to the development of pathological changes in this organ at a later stage. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12226812     DOI: 10.1002/jemt.10156

Source DB:  PubMed          Journal:  Microsc Res Tech        ISSN: 1059-910X            Impact factor:   2.769


  4 in total

Review 1.  Alkaline phosphatase: a novel treatment target for cardiovascular disease in CKD.

Authors:  Mathias Haarhaus; Vincent Brandenburg; Kamyar Kalantar-Zadeh; Peter Stenvinkel; Per Magnusson
Journal:  Nat Rev Nephrol       Date:  2017-05-15       Impact factor: 28.314

2.  Endotoxin- and ATP-neutralizing activity of alkaline phosphatase as a strategy to limit neuroinflammation.

Authors:  Ruth Huizinga; Karim L Kreft; Sabina Onderwater; Joke G Boonstra; Ruud Brands; Rogier Q Hintzen; Jon D Laman
Journal:  J Neuroinflammation       Date:  2012-12-11       Impact factor: 8.322

3.  E-NTPDases in human airways: Regulation and relevance for chronic lung diseases.

Authors:  Lauranell H Burch; Maryse Picher
Journal:  Purinergic Signal       Date:  2006-05-30       Impact factor: 3.765

4.  Sex-dependent, zinc-induced dephosphorylation of phospholamban by tissue-nonspecific alkaline phosphatase in the cardiac sarcomere.

Authors:  Yuan Wang; Nicole M Bishop; Douglas J Taatjes; Sonoko Narisawa; José Luis Millán; Bradley M Palmer
Journal:  Am J Physiol Heart Circ Physiol       Date:  2014-07-11       Impact factor: 4.733

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.